Uquifa SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Uquifa SA - overview
Location
Barcelona, -, Spain
Primary Industry
Pharmaceuticals
About
Uquifa SA is a Spanish company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates for the pharmaceutical and animal health sectors, with a commitment to quality and regulatory compliance. Uquifa SA is focused on the production of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is headquartered in Barcelona, Spain. Paolo Fichera serves as the CEO.
In January 2018, the company secured USD 7. 5 million in a GROWTH round from OrbiMed Advisors, raising the total amount raised to USD 7. 5 million through three deals, with the most recent deal occurring on January 2, 2017. Uquifa Group specializes in the manufacture of Active Pharmaceutical Ingredients (APIs) and intermediates tailored for the pharmaceutical and animal health sectors.
With over 85 years of industry experience, Uquifa's service offering extends from proof of concept to commercial manufacture, utilizing a reliable quality manufacturing platform that adheres to stringent regulatory standards. Their core product portfolio focuses on off-patent APIs, crucial for generic drug formulations, and proprietary intermediates that aid in the development of innovative therapeutics, serving clients in over 70 countries, including major global generic and ethical pharmaceutical companies. In the most recent financial year, Uquifa Group reported a revenue of USD 118. 36 mn and an EBITDA of USD 6.
35 mn. Their revenue generation is primarily through business-to-business transactions with pharmaceutical manufacturers, ensuring a consistent flow of orders through long-term partnerships. Uquifa’s flagship products, including various off-patent APIs, play an integral role in the production of generic drugs, contributing significantly to their revenue stream. Uquifa aims to leverage the recent funding of USD 7.
5 million from OrbiMed Advisors to enhance its product offerings and market reach. The company plans to design and launch new APIs targeted for release in the upcoming years. Additionally, Uquifa is exploring expansion into new geographic markets to increase its global footprint, with specific efforts directed toward North America and Asia by the end of 2025. This strategic approach will further solidify Uquifa's position in the pharmaceutical industry.
Current Investors
Vivimed Labs Ltd., OrbiMed Advisors, InvAscent Capital Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.uquifa.com
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Uquifa SA - timeline of key events
Uquifa SA - financials
| Fiscal Year Ended | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 3,286,000 | 5,371,000 | 5,306,000 | 5,202,000 | 8,142,000 | - | - | - | - | - |
| % Revenue Growth (YoY) | - | 63.5% | (1.2%) | (2.0%) | 56.5% | (100.0%) | - | - | - | - |
| EBITDA (USD) | 3,013,000 | 4,867,000 | 4,758,000 | 4,566,000 | 7,882,000 | (296,000) | (296,000) | - | - | - |
| Operating Income (USD) | 3,013,000 | 4,867,000 | 4,758,000 | 4,566,000 | 7,882,000 | (296,000) | (296,000) | - | - | - |
| Operating Margin | 91.7% | 90.6% | 89.7% | 87.8% | 96.8% | - | - | - | - | - |
| % EBITDA Margin | 91.7% | 90.6% | 89.7% | 87.8% | 96.8% | - | - | - | - | - |
| NET Income (USD) | 2,918,000 | 3,462,000 | 6,832,000 | 2,846,000 | 6,560,000 | (1,251,000) | (1,251,000) | - | - | - |
| % Net Margin | 88.8% | 64.5% | 128.8% | 54.7% | 80.6% | - | - | - | - | - |
Uquifa SA - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | Uquifa SA | - | ||||||||
| Add-on | Completed | Uquifa SA | - | ||||||||
| Buyout | Completed | Uquifa SA | - |
Displaying 1 - 3 of 3
Uquifa SA - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.